USANA Health Sciences Files 8-K Report
Ticker: USNA · Form: 8-K · Filed: Jul 23, 2024 · CIK: 896264
| Field | Detail |
|---|---|
| Company | Usana Health Sciences Inc (USNA) |
| Form Type | 8-K |
| Filed Date | Jul 23, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, sec-filing
Related Tickers: USNA
TL;DR
USANA Health Sciences dropped an 8-K on 7/23 - check financials and operations.
AI Summary
On July 23, 2024, USANA Health Sciences, Inc. filed an 8-K report detailing its financial results and other relevant information. The filing includes information on the company's operations, financial condition, and exhibits.
Why It Matters
This 8-K filing provides investors with crucial updates on USANA Health Sciences' financial performance and operational status, impacting investment decisions.
Risk Assessment
Risk Level: low — This is a routine SEC filing providing financial and operational updates, not indicating any immediate or significant new risks.
Key Players & Entities
- USANA HEALTH SCIENCES, INC. (company) — Registrant
- July 23, 2024 (date) — Date of Report
- Utah (location) — State of Incorporation
- Salt Lake City (location) — Principal Executive Offices City
FAQ
What is the primary purpose of this Form 8-K filing for USANA Health Sciences, Inc.?
The primary purpose of this Form 8-K filing is to report on the Results of Operations and Financial Condition, Regulation FD Disclosure, and Financial Statements and Exhibits of USANA Health Sciences, Inc.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on July 23, 2024.
In which state is USANA Health Sciences, Inc. incorporated?
USANA Health Sciences, Inc. is incorporated in Utah.
What is the business address of USANA Health Sciences, Inc.?
The business address of USANA Health Sciences, Inc. is 3838 West Parkway Boulevard, Salt Lake City, Utah 84120.
What is the SEC file number for USANA Health Sciences, Inc.?
The SEC file number for USANA Health Sciences, Inc. is 001-35024.
Filing Stats: 700 words · 3 min read · ~2 pages · Grade level 10.4 · Accepted 2024-07-23 16:11:05
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value per share USNA New York Stock
Filing Documents
- usna-20240723.htm (8-K) — 27KB
- q22024earningsreleaseex9911.htm (EX-99.1) — 156KB
- q22024managementcommentary.htm (EX-99.2) — 70KB
- usanacorplogoresized1.jpg (GRAPHIC) — 9KB
- usanacorplogoresizeda.jpg (GRAPHIC) — 9KB
- 0000896264-24-000180.txt ( ) — 422KB
- usna-20240723.xsd (EX-101.SCH) — 2KB
- usna-20240723_lab.xml (EX-101.LAB) — 21KB
- usna-20240723_pre.xml (EX-101.PRE) — 12KB
- usna-20240723_htm.xml (XML) — 3KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On July 23, 2024, USANA Health Sciences, Inc. (the "Company" or "USANA") issued a press release announcing its financial results for the second quarter ended June 29, 2024. The release also announced that the Company will post a document titled "Management Commentary" on the Company's website and that executives of the Company will hold a conference call with investors, to be broadcast over the World Wide Web and by telephone and provided access information, date and time for the conference call. The Company noted that the call will consist of brief remarks by the Company's management team, before moving directly into questions and answers. A copy of the press release, and the Management Commentary, are furnished herewith as Exhibits 99.1 and 99.2 to this Current Report on Form 8-K and are incorporated herein by reference. These documents will be posted on the Company's corporate website, www.usana.com. The information in this Current Report is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Current Report, including the exhibits, shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended. The furnishing of the information in this Current Report is not intended to, and does not, constitute a representation that such furnishing is required by Regulation FD or that the information this Current Report contains is material investor information that is not otherwise publicly available.
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure The information disclosed above under Item 2.02, as well as the exhibits attached under Item 9.01 below are incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release issued by USANA Health Sciences, Inc. dated July 23 , 2024 (furnished herewith). 99.2 Management Commentary provided by USANA Health Sciences, Inc. dated July 23 , 2024 (furnished herewith). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. USANA HEALTH SCIENCES, INC. By: /s/ G. Douglas Hekking G. Douglas Hekking, Chief Financial Officer Date: July 23, 2024